Federal Judge Halts Lawsuit Challenging FDA Mifepristone Rules, National Access Remains Unchanged
A federal judge in Louisiana has temporarily halted a lawsuit challenging the Food and Drug Administration's (FDA) 2023 rule changes, which permitted mifepristone to be prescribed via telemedicine and dispensed by mail. The ruling by Judge David C. Joseph grants the FDA's request to complete its own safety review of the medication.
This decision means national access to mifepristone is to remain unchanged for the present time, amidst ongoing discussions about abortion access following the 2022 reversal of Roe v. Wade.
Background on Mifepristone
Mifepristone has been utilized in the United States for over 25 years for first-trimester abortion and miscarriage management. The medical community generally regards the medication as safe and effective.
The FDA has historically adjusted its regulations regarding access to mifepristone. The specific 2023 modification at the center of the lawsuit removed the requirement for an in-person appointment for its prescription, allowing virtual consultations and mail delivery.
The Legal Challenge
The lawsuit was initiated by the state of Louisiana, joined by a Louisiana patient, challenging the FDA's 2023 rule alteration.
The complaint, filed in October, alleged that the FDA's changes aimed to circumvent the Supreme Court's Dobbs decision by facilitating the mailing of mifepristone into states with abortion restrictions, thereby causing harm to Louisiana and certain individuals.
The FDA is the defendant in the case, with mifepristone drugmakers GenBioPro and Danco Laboratories having been permitted to intervene to defend their medications. Louisiana has previously taken actions regarding abortion access, including classifying mifepristone as a controlled substance and pursuing criminal charges against an out-of-state physician for providing telemedicine abortion services.
Judge's Ruling and FDA Review
Judge David C. Joseph issued a 37-page ruling on Tuesday, granting the FDA's request to stay the case. The FDA had sought the stay to conduct its own safety review of mifepristone.
While acknowledging Louisiana's arguments regarding potential harms, Judge Joseph stated that the FDA possesses the necessary expertise to evaluate scientific evidence and make public health judgments. The judge ordered the FDA to provide an update to the court on its review progress within six months.
This ruling ensures that national access to the medication will remain unchanged during this period.
Broader Context of Abortion Access and Telemedicine
The legal challenge unfolds against a backdrop of stable abortion numbers in the U.S. despite state-level bans and restrictions enacted since the 2022 reversal of Roe v. Wade. A report from the Guttmacher Institute, a research organization, estimated approximately 1.1 million abortions were provided in the U.S. in 2023, a figure consistent with the prior year.
Telemedicine has emerged as a significant factor in maintaining abortion access. The FDA's 2023 decision to allow mifepristone prescription without an in-person appointment facilitated this. Additionally, states that support abortion access have implemented "shield laws" designed to protect healthcare providers from legal risks when prescribing medication to patients in states with abortion bans.
This development has led to an increase in individuals in states with restrictions accessing abortions via telemedicine. In 2023, an estimated 91,000 patients in states with abortion bans received telehealth abortions. In Louisiana specifically, abortions increased from approximately 2,500 in 2022 to over 9,000 in 2023, according to Guttmacher Institute data.
Opponents of abortion access have voiced concerns regarding these developments, leading to multiple legal challenges and proposals for a Congressional bill aimed at preventing the FDA from allowing mifepristone to be mailed to patients. Misoprostol, another medication used in abortion, faces fewer restriction attempts.